![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment ... Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.34 | 11.3333333333 | 3 | 3.62 | 2.9 | 469232 | 3.17724519 | CS |
4 | -0.77 | -18.7347931873 | 4.11 | 4.29 | 2.78 | 463970 | 3.52067251 | CS |
12 | -0.84 | -20.0956937799 | 4.18 | 5.7 | 2.78 | 512664 | 4.36820256 | CS |
26 | -4.86 | -59.2682926829 | 8.2 | 20.71 | 2.78 | 1149253 | 9.57073395 | CS |
52 | -12.3 | -78.6445012788 | 15.64 | 20.71 | 2.13 | 637751 | 9.43661224 | CS |
156 | -12.16 | -78.4516129032 | 15.5 | 20.71 | 2.13 | 638824 | 9.47356286 | CS |
260 | -12.16 | -78.4516129032 | 15.5 | 20.71 | 2.13 | 638824 | 9.47356286 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions